P868: Mezigdomide (Mezi) Plus Dexamethasone (Dex) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (Rrmm): Results From the Dose-Expansion Phase of the Cc-92480-Mm-001 Trial

Abstract

Background:MEZI, a novel oral cereblon E3 ligase modulator (CELMoD ™ ) with enhanced tumoricidal and immune-stimulatory effects compared with IMiD ® agents, induces maximal Ikaros/Aiolos degradation, leading to increased apoptosis in MM cells. Preclinically, MEZI demonstrated potent synergy with DEX, proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (mAbs). In phase 1 of CC-92480-MM-001 (NCT03374085), the recommended phase 2 dose (RP2D) of MEZI + DEX (Mezi-d) was selected at 1 mg once daily for 21/28 days.